Covered recipient · General Payments record
EVAGELOS COSKINAS
Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$92.48
5 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $92.48 | 5 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | $44.65 | 3 |
| Alkermes, Inc. | $24.44 | 1 |
| Janssen Pharmaceuticals, Inc | $23.39 | 1 |
Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
EVAGELOS COSKINAS
NPI 1437382314 · CMS profile ID 201763
Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry
RIVERSIDE, CA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1437382314?year=2019&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- EVAGELOS COSKINAS, NPI 1437382314, CMS profile ID 201763. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1437382314?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). EVAGELOS COSKINAS, NPI 1437382314, CMS profile ID 201763. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1437382314?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- EVAGELOS COSKINAS, NPI 1437382314, CMS profile ID 201763, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1437382314?year=2019&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
5 matching records · $92.48 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–5 of 5.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Sunovion Pharmaceuticals Inc. | $11.75 | 09/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688090291 | CMS |
| Sunovion Pharmaceuticals Inc. | $16.19 | 06/21/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688090289 | CMS |
| Janssen Pharmaceuticals, Inc | $23.39 | 03/28/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658463767 | CMS |
| Sunovion Pharmaceuticals Inc. | $16.71 | 02/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688090287 | CMS |
| Alkermes, Inc. | $24.44 | 02/07/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 686582037 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $5,435,713.44 | 192 |
| PY2024 | Principal investigator | $1,112,891.48 | 274 |
| PY2023 | Principal investigator | $145,338.68 | 81 |
| PY2021 | Principal investigator | $14,588.05 | 4 |
| PY2020 | Principal investigator | $129,452.46 | 74 |
| PY2019 | Principal investigator | $432,130.59 | 40 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
192 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $15,200.00 | 12/19/2025 | Non-covered Recipient Entity Clinical Innovations, Incorporated | A Phase 3, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Manic Episodes or Mixed Manic Episodes in Individuals with Bipolar-I Disorder and Inadequate Response to Lithium, Valproate, or Lamotrigine | No dispute reported | 06/30/2026 | 1235998080 |
| Principal investigator 1 | BioXcel Therapeutics, Inc. | $3,650.00 | 12/09/2025 | Non-covered Recipient Entity CITRIALS | BXCL501401 | No dispute reported | 06/30/2026 | 1228698342 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 12/05/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242368761 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $108.00 | 12/05/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242368763 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $89.00 | 12/05/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242368765 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $1,897.00 | 11/21/2025 | Non-covered Recipient Entity Clinical Innovations, Incorporated | A Phase 3, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Manic Episodes or Mixed Manic Episodes in Individuals with Bipolar-I Disorder and Inadequate Response to Lithium, Valproate, or Lamotrigine | No dispute reported | 06/30/2026 | 1235998074 |
| Principal investigator 1 | BioXcel Therapeutics, Inc. | $756.68 | 11/17/2025 | Non-covered Recipient Entity CITRIALS | BXCL501401 | No dispute reported | 06/30/2026 | 1228698326 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 11/13/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242366017 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 11/13/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242366019 |
| Principal investigator 1 | BioXcel Therapeutics, Inc. | $476.55 | 11/04/2025 | Non-covered Recipient Entity CITRIALS | BXCL501401 | No dispute reported | 06/30/2026 | 1228698310 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 10/28/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242365049 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 10/28/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242365051 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 10/28/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242365053 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 10/28/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242365055 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 10/28/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242365057 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 10/28/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242365059 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 10/28/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242365061 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 10/10/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242363527 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 10/10/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242363529 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 10/10/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242363531 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 10/10/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242363533 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 10/10/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242363535 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 10/10/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242363537 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 10/10/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242363539 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 10/10/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242363541 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 10/10/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242363543 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 10/10/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242363545 |
| Principal investigator 1 | BioXcel Therapeutics, Inc. | $1,513.36 | 10/06/2025 | Non-covered Recipient Entity CITRIALS | BXCL501401 | No dispute reported | 06/30/2026 | 1228698270 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 09/22/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242359118 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $108.00 | 09/22/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242359120 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $89.00 | 09/22/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242359122 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $16,000.00 | 09/18/2025 | Non-covered Recipient Entity Clinical Innovations, Incorporated | A Phase 3, Open-label Extension Study to Assess the Long-term Safety of KarXT for the Treatment of Mania or Mania with Mixed Features in Bipolar-I Disorder | No dispute reported | 06/30/2026 | 1235998078 |
| Principal investigator 1 | BioXcel Therapeutics, Inc. | $28,687.11 | 09/15/2025 | Non-covered Recipient Entity CITRIALS | BXCL501401 | No dispute reported | 06/30/2026 | 1228698254 |
| Principal investigator 1 | BioXcel Therapeutics, Inc. | $4,734.93 | 09/15/2025 | Non-covered Recipient Entity CITRIALS | BXCL501401 | No dispute reported | 06/30/2026 | 1228698256 |
| Principal investigator 1 | ABBVIE INC. | $1,500.00 | 09/09/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia | No dispute reported | 06/30/2026 | 1202510370 |
| Principal investigator 1 | ABBVIE INC. | $650.00 | 09/04/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia | No dispute reported | 06/30/2026 | 1202510106 |
| Principal investigator 1 | ABBVIE INC. | $33,984.50 | 08/27/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of CVL-231(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis | No dispute reported | 06/30/2026 | 1202506217 |
| Principal investigator 1 | ABBVIE INC. | $20,147.80 | 08/27/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of CVL-231(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis | No dispute reported | 06/30/2026 | 1202506219 |
| Principal investigator 1 | ABBVIE INC. | $17,784.20 | 08/27/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of CVL-231(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis | No dispute reported | 06/30/2026 | 1202506221 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $1,356.63 | 08/26/2025 | Non-covered Recipient Entity Precise Research Center | A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder | No dispute reported | 06/30/2026 | 1235994571 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $203.92 | 08/26/2025 | Non-covered Recipient Entity Precise Research Center | Phase III Safety and Efficacy of KarXT in Psychosis Associated with AD (ADEPT 4): 2 of 2 Acute Studies | No dispute reported | 06/30/2026 | 1235994573 |
| Principal investigator 1 | Axsome Therapeutics, Inc. | $2,119.44 | 08/13/2025 | Non-covered Recipient Entity Clinical Innovations, Inc. | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | No dispute reported | 06/30/2026 | 1199917430 |
| Principal investigator 1 | BioXcel Therapeutics, Inc. | $300.00 | 08/11/2025 | Non-covered Recipient Entity CITRIALS | BXCL501401 | No dispute reported | 06/30/2026 | 1228698218 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $2,650.05 | 07/31/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia | No dispute reported | 06/30/2026 | 1244049853 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $2,817.92 | 07/31/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia | No dispute reported | 06/30/2026 | 1244049855 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $544.72 | 07/28/2025 | Non-covered Recipient Entity Guardian Angel Research Center | Phase III Safety and Efficacy of KarXT in Psychosis Associated with AD (ADEPT 4): 2 of 2 Acute Studies | No dispute reported | 06/30/2026 | 1235997031 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $1,393.37 | 07/28/2025 | Non-covered Recipient Entity Clinical Innovations, Incorporated | A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder | No dispute reported | 06/30/2026 | 1235998072 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $1,471.67 | 07/28/2025 | Non-covered Recipient Entity Clinical Innovations, Incorporated | A Phase 3, Open-label Extension Study to Assess the Long-term Safety of KarXT for the Treatment of Mania or Mania with Mixed Features in Bipolar-I Disorder | No dispute reported | 06/30/2026 | 1235998076 |
| Principal investigator 1 | Axsome Therapeutics, Inc. | $2,180.00 | 07/23/2025 | Non-covered Recipient Entity Clinical Innovations, Inc. | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | No dispute reported | 06/30/2026 | 1199917428 |
| Principal investigator 1 | ABBVIE INC. | $115,783.11 | 07/16/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of CVL-231(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis | No dispute reported | 06/30/2026 | 1202498468 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 07/16/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242353725 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 07/16/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242353727 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 07/16/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242353729 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 07/16/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242353731 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 07/16/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242353733 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 07/16/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242353735 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 07/16/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242353737 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 07/16/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242353739 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 07/16/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242353741 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 07/16/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242353743 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 07/16/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242353745 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 07/16/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242353747 |
| Principal investigator 1 | BioXcel Therapeutics, Inc. | $2,974.54 | 07/08/2025 | Non-covered Recipient Entity CITRIALS | BXCL501401 | No dispute reported | 06/30/2026 | 1228698190 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 07/07/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242352883 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 07/07/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242352885 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 07/07/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242352887 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $8,767.21 | 06/25/2025 | Non-covered Recipient Entity The Start Center For Cancer Care | A Phase 1/2a, Open-label, Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BMS-986507 (BL-B01D1) combinations in Adult Participants with Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1235993057 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,000.00 | 06/24/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia | No dispute reported | 06/30/2026 | 1244049847 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $2,746.00 | 06/24/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia | No dispute reported | 06/30/2026 | 1244049849 |
| Principal investigator 1 | BioXcel Therapeutics, Inc. | $8,090.94 | 06/19/2025 | Non-covered Recipient Entity CITRIALS | BXCL501401 | No dispute reported | 06/30/2026 | 1228698078 |
| Principal investigator 1 | BioXcel Therapeutics, Inc. | $25,641.97 | 06/19/2025 | Non-covered Recipient Entity CITRIALS | BXCL501401 | No dispute reported | 06/30/2026 | 1228698080 |
| Principal investigator 1 | Axsome Therapeutics, Inc. | $427.95 | 06/13/2025 | Non-covered Recipient Entity Clinical Innovations, Inc. | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | No dispute reported | 06/30/2026 | 1199917424 |
| Principal investigator 1 | Axsome Therapeutics, Inc. | $7,834.14 | 06/13/2025 | Non-covered Recipient Entity Clinical Innovations, Inc. | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | No dispute reported | 06/30/2026 | 1199917426 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 06/13/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242350288 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 06/13/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242350290 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 06/13/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242350294 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 06/13/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242350296 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 06/13/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242350298 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 06/13/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242350300 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 06/13/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242350302 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 06/13/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242350304 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 06/13/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242350306 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 06/13/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242350366 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 06/13/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242350768 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 06/13/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242350770 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 06/13/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242350772 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 06/13/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242350774 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 06/13/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242350776 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 06/13/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242350778 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 06/13/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242350780 |
| Principal investigator 1 | ABBVIE INC. | $5,397.60 | 06/04/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC DBA CITRIALS | A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder | No dispute reported | 06/30/2026 | 1202490157 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $55,500.00 | 05/28/2025 | Non-covered Recipient Entity Citrials | An 8-week Open-label, Multicenter Randomized Study of Accelerated and Slower Switching to Xanomeline/Trospium Following Atypical Antipsychotic Treatment to Assess the Safety, Tolerability, and Efficacy in Participants with DSM-5 Schizophrenia | No dispute reported | 06/30/2026 | 1235998144 |
| Principal investigator 1 | BioXcel Therapeutics, Inc. | $120.00 | 05/20/2025 | Non-covered Recipient Entity CITRIALS | BXCL501401 | No dispute reported | 06/30/2026 | 1228698022 |
| Principal investigator 1 | Axsome Therapeutics, Inc. | $89.62 | 05/16/2025 | Non-covered Recipient Entity Clinical Innovations, Inc. | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | No dispute reported | 06/30/2026 | 1199917422 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $104,092.69 | 05/14/2025 | Non-covered Recipient Entity Clinical Innovations, Incorporated | A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder | No dispute reported | 06/30/2026 | 1235998070 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 05/07/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242346619 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $8,096.00 | 05/07/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242346621 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 05/07/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242346623 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 05/07/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242346625 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 05/07/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242346627 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 05/07/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242346629 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 05/07/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242346647 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 05/07/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242346649 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 05/07/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242346651 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 05/07/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242346653 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 05/07/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242346655 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 05/07/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242346657 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 05/07/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242346677 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 05/07/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242346679 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 05/07/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242346681 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 05/07/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242346683 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 05/07/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242346685 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 05/07/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242346687 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $6,874.00 | 05/07/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242346689 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,966.00 | 05/07/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242346721 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $4,497.00 | 05/07/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242346723 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 05/07/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242347180 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 05/07/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242347182 |
| Principal investigator 1 | ABBVIE INC. | $900.00 | 04/28/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC DBA CITRIALS | A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder | No dispute reported | 06/30/2026 | 1202479793 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 04/11/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242343249 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 04/11/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242343253 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $8,096.00 | 04/11/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242343255 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $7,412.00 | 04/11/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242343257 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $6,036.00 | 04/11/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242343259 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $8,096.00 | 04/11/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242343363 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 04/11/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242343365 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 04/11/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242343367 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 04/11/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242343369 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 04/11/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242343371 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $8,096.00 | 04/11/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242343373 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 04/11/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242343375 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 04/11/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242343377 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 04/11/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242343379 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 04/11/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242343381 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 04/11/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242343383 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 04/11/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242343385 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $8,096.00 | 04/11/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242343387 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 04/11/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242343389 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 04/11/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242343391 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 04/11/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242343393 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 04/11/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242343395 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 04/11/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242343397 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 04/11/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242343399 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $8,096.00 | 04/11/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242343401 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 04/11/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242343403 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 04/11/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242343405 |
| Principal investigator 1 | ABBVIE INC. | $2,500.00 | 04/02/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia | No dispute reported | 06/30/2026 | 1202468576 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $3,039.00 | 04/01/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia | No dispute reported | 06/30/2026 | 1244049839 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $500.00 | 04/01/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia | No dispute reported | 06/30/2026 | 1244049841 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $2,000.00 | 04/01/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia | No dispute reported | 06/30/2026 | 1244049843 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,500.00 | 04/01/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia | No dispute reported | 06/30/2026 | 1244049845 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $8,096.00 | 03/12/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242336911 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/12/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242336913 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $8,096.00 | 03/12/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242336915 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/12/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242336917 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/12/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242336919 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/12/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242336921 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/12/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242336923 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/12/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242336997 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $8,096.00 | 03/12/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242336999 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $1,897.00 | 03/12/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242337001 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $1,897.00 | 03/12/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242337003 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/12/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242337219 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/12/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242337221 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/12/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242337223 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $45.00 | 03/12/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242337225 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/12/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242337227 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/12/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242337285 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/12/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242337287 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/12/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242337289 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/12/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242337291 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/12/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242337293 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/12/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242337295 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 03/12/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242337297 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $6.93 | 03/12/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242337859 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,597.00 | 03/12/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242337861 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16,968.00 | 03/03/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242334592 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $2,381.40 | 02/05/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia | No dispute reported | 06/30/2026 | 1244049837 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $4,256,444.00 | 01/22/2025 | Non-covered Recipient Entity Cenexel Cit | A Phase 3b, Open-label, Multicenter, Two-Period, Slow-titration and Food Effect Study to Assess the Safety and Efficacy of KarXT in Participants with DSM-5 Schizophrenia | No dispute reported | 06/30/2026 | 1235998302 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 01/22/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242328717 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $6,874.00 | 01/22/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242328719 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $20,000.00 | 01/22/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242328753 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,966.00 | 01/22/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242328759 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,828.00 | 01/22/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242328761 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $4,497.00 | 01/22/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242328763 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,597.00 | 01/22/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242328765 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $4,497.00 | 01/22/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242328767 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,966.00 | 01/22/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242328769 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $4,497.00 | 01/22/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242328771 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $6,874.00 | 01/22/2025 | Non-covered Recipient Entity CLINICAL INNOVATIONS INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242329741 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $112,583.49 | 01/06/2025 | Non-covered Recipient Entity Cenexel Cit | A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia (ARISE) | No dispute reported | 06/30/2026 | 1235998306 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $59,250.00 | 01/03/2025 | Non-covered Recipient Entity Cenexel Cit | An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia | No dispute reported | 06/30/2026 | 1235998304 |